Migraine is a common and disabling neurological disorder that is often difficult to manage, despite treatments such as triptans, non-steroidal anti-inflammatory drugs (NSAIDs), and calcitonin gene-related peptide (CGRP)-targeted therapies. Lacosamide, an antiepileptic medication, has emerged as a potential new treatment option. This drug enhances slow inactivation of voltage-gated sodium channels and modulates collapsin response mediator protein-2 (CRMP2), and consequently may help decrease neuronal overactivity and limit the release of CGRP, a key driver of migraine pain. Animal studies have shown that lacosamide suppresses trigeminal CGRP release, and early clinical findings suggest that it might lower migraine frequency and severity. However, because current evidence is limited by small patient numbers and short follow-up periods, questions persist regarding its long-term safety and effectiveness. Larger well-designed studies are needed to determine whether lacosamide might offer a meaningful new approach for patients with refractory migraine, beyond its role in epilepsy treatment.
Mehroz Mustafa (Thu,) studied this question.